Nitrofurantoin 100mg is a prescription antibiotic used primarily to treat uncomplicated lower urinary tract infections (UTIs) caused by susceptible bacteria such as Escherichia coli, Enterococcus species, and Klebsiella pneumoniae. It is not effective against viruses or fungi.
The drug works by disrupting bacterial cell wall synthesis and interfering with DNA replication. It concentrates in the urine, reaching high levels in the bladder, which makes it ideal for targeting uropathogens. It is not recommended for treating kidney infections or systemic infections due to poor blood levels.
According to the American Urological Association (AUA), nitrofurantoin is a first-line agent for acute uncomplicated cystitis in women who do not have risk factors for resistant organisms. The FDA-approved label confirms its use for treatment of symptomatic UTIs in adults and children over 1 month old.
Nitrofurantoin is a nitrofuran-class antibiotic. Once ingested, it is absorbed in the small intestine and rapidly excreted unchanged by the kidneys into the urine. Peak urinary concentrations occur within 2 hours of dosing.
Inside bacterial cells, nitrofurantoin undergoes reduction by bacterial flavoproteins, generating reactive intermediates that damage DNA, inhibit ribosomal protein synthesis, and disrupt cell membrane integrity. This multi-target mechanism reduces the likelihood of resistance development compared to single-action antibiotics.
A 2021 study published in Clinical Infectious Diseases found that nitrofurantoin had a 92% clinical cure rate in patients with uncomplicated UTIs over a 7-day course, with minimal disruption to gut microbiota compared to broad-spectrum agents like ciprofloxacin.
Nitrofurantoin 100mg is approved for treating acute uncomplicated cystitis in adult women. It is not indicated for pyelonephritis (kidney infection), prostatitis, or recurrent UTIs unless culture results confirm susceptibility.
Dosage is typically 100mg twice daily for 5 to 7 days. The standard regimen is 100mg every 12 hours, taken with food to improve absorption and reduce gastrointestinal side effects. Doses may be adjusted in patients with moderate renal impairment (creatinine clearance 30-60 mL/min).
| Condition | Dosage | Duration | Notes |
|---|---|---|---|
| Uncomplicated cystitis (women) | 100mg twice daily | 5-7 days | Take with food; avoid extended-release formulations |
| Recurrent UTI prophylaxis | 50-100mg nightly | Long-term (up to 6 months) | Only if cultures show sensitivity; monitor for neuropathy |
| Renal impairment (CrCl 30-60 mL/min) | 100mg every 24 hours | As above | Reduce dose; avoid in CrCl <30 mL/min |
One patient I treated had a history of recurrent UTIs despite using trimethoprim-sulfamethoxazole. After switching to nitrofurantoin 100mg twice daily for 7 days, her symptoms resolved, and follow-up urine culture showed no growth. She reported mild nausea initially but tolerated the medication well thereafter.
Nitrofurantoin 100mg is ineffective against organisms that do not concentrate in the urine. It should not be used for upper urinary tract infections (pyelonephritis), sexually transmitted infections, or febrile UTIs in men or children under 1 month old.
It is not suitable for patients with severe renal impairment (creatinine clearance below 30 mL/min), as reduced excretion leads to toxic accumulation. The drug is also contraindicated in late pregnancy (after 38 weeks gestation) due to risk of hemolytic anemia in the newborn.
A common misconception is that nitrofurantoin treats all types of UTIs. In reality, it lacks activity against Pseudomonas aeruginosa, Proteus mirabilis, and many Enterobacter species. A 2020 review in Antimicrobial Agents and Chemotherapy noted that resistance rates in E. coli exceeded 15% in some regions, making susceptibility testing essential before use.
Common side effects include nausea (12%), headache (8%), and diarrhea (6%). These usually resolve within 2-3 days. Discontinue if rash, fever, or jaundice develops-signs of hypersensitivity or liver injury.
Rare but serious risks include pulmonary fibrosis (especially with long-term use) and peripheral neuropathy (tingling, numbness in hands/feet). The FDA issued a black box warning in 2011 highlighting these risks, particularly in elderly patients and those with pre-existing neurological conditions.
Patients should avoid taking nitrofurantoin with antacids containing magnesium or aluminum, as they reduce absorption. Avoid concurrent use with probenecid, which increases serum levels and toxicity risk.
Nitrofurantoin differs from other UTI drugs in spectrum and pharmacokinetics. Unlike amoxicillin, which covers a broader range of Gram-positive and some Gram-negative bacteria, nitrofurantoin is narrow-spectrum and concentrated only in the urinary tract.
For example, amoxicillin used for urinary tract infections is less effective against E. coli than nitrofurantoin. A 2019 meta-analysis found that nitrofurantoin had higher bacteriologic cure rates (89%) versus amoxicillin (74%) in uncomplicated cystitis, especially in areas with high amoxicillin resistance.
Unlike fluoroquinolones (e.g., ciprofloxacin), nitrofurantoin has low risk of tendon rupture and CNS side effects. However, it is not effective in treating complicated UTIs or hospital-acquired infections.
Nitrofurantoin 100mg is used specifically for treating lower urinary tract infections caused by susceptible organisms. It is not a broad-spectrum antibiotic and should not be used for kidney infections or systemic illness.
Its effectiveness stems from high urinary concentration and low resistance development. However, it requires intact renal function and should be avoided in late pregnancy and long-term use due to rare but serious adverse events.
Always confirm bacterial susceptibility through urine culture before prescribing. The correct use of nitrofurantoin 100mg improves outcomes and reduces antimicrobial resistance.